Introduced by Novo Nordisk in 2026, oral semaglutide became the first oral GLP-1 medication approved explicitly for weight loss
Skin feels plumper and more hydrated after
While side effect profiles are expected to mirror those of injectable semaglutide (such as nausea, vomiting, and constipation), the incidence and severity remain to be fully characterized through larger-scale trials
Naseem MU, Carcamo-Noriega E, Beltrn-Vidal J, Borrego J, Szanto TG, Zamudio FZ et al (2022) Cm28, a Scorpion toxin having a unique primary structure, inhibits K V 1.2 and K V 1.3 with high affinity
A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine
First, potential administrative costs and rebates associated with implementing and managing formulary restrictions were not accounted for